NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01187381

TerminatedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Interventions: Trastuzumab

Countries: Romania

This single arm observational study will assess the duration and safety of treatment with trastuzumab in routine clinical practice in participants with early or metastatic HER2-positive breast cancer. Data will be collected from female participants treated with trastuzumab according to the Summary of Product Characteristics and local protocols. Duration of observation for each participant is from therapy initiation until permanent discontinuation for any cause.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* HER2-positive breast cancer
* Treated with trastuzumab in accordance with Summary of Product Characteristics and local protocols
* Written informed consent to data collection

Exclusion Criteria:

* Any contraindication to trastuzumab
* Clinically relevant cardiovascular disorder or disease

Locations (1)

Cluj-Napoca, Romania